Stifel Nicolaus Forecasts Strong Price Appreciation for KalVista Pharmaceuticals (NASDAQ:KALV) Stock

KalVista Pharmaceuticals (NASDAQ:KALV) had its price target lifted by investment analysts at Stifel Nicolaus from $39.00 to $42.00 in a report released on Thursday,Benzinga reports. The firm presently has a “buy” rating on the specialty pharmaceutical company’s stock. Stifel Nicolaus’ price target points to a potential upside of 117.28% from the company’s previous close.

Several other equities research analysts also recently commented on the company. Wall Street Zen raised KalVista Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, December 6th. Citizens Jmp lowered their target price on shares of KalVista Pharmaceuticals from $29.00 to $28.00 and set a “market outperform” rating on the stock in a report on Thursday. Needham & Company LLC upped their price target on shares of KalVista Pharmaceuticals from $35.00 to $36.00 and gave the stock a “buy” rating in a research report on Wednesday. Weiss Ratings reissued a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a research report on Thursday, January 22nd. Finally, TD Cowen restated a “buy” rating on shares of KalVista Pharmaceuticals in a research note on Wednesday, December 3rd. Seven equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, KalVista Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $32.60.

KalVista Pharmaceuticals Stock Performance

Shares of KALV opened at $19.33 on Thursday. The stock has a market capitalization of $990.08 million, a price-to-earnings ratio of -4.89 and a beta of -0.35. KalVista Pharmaceuticals has a 12 month low of $9.23 and a 12 month high of $19.95. The firm has a fifty day simple moving average of $16.04 and a 200 day simple moving average of $14.46. The company has a current ratio of 7.22, a quick ratio of 7.21 and a debt-to-equity ratio of 8.18.

Insiders Place Their Bets

In related news, insider Nicole Sweeny sold 3,975 shares of the firm’s stock in a transaction on Monday, February 23rd. The stock was sold at an average price of $15.57, for a total value of $61,890.75. Following the transaction, the insider owned 47,003 shares in the company, valued at approximately $731,836.71. This trade represents a 7.80% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Benjamin L. Palleiko sold 10,034 shares of the firm’s stock in a transaction dated Monday, February 23rd. The shares were sold at an average price of $15.57, for a total transaction of $156,229.38. Following the completion of the transaction, the chief executive officer directly owned 442,883 shares in the company, valued at approximately $6,895,688.31. This represents a 2.22% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 248,009 shares of company stock valued at $4,213,467 in the last three months. Insiders own 4.30% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in KALV. Vanguard Group Inc. lifted its stake in KalVista Pharmaceuticals by 3.7% in the 3rd quarter. Vanguard Group Inc. now owns 2,501,119 shares of the specialty pharmaceutical company’s stock valued at $30,464,000 after purchasing an additional 88,720 shares during the last quarter. Tudor Investment Corp ET AL bought a new stake in shares of KalVista Pharmaceuticals during the third quarter worth $24,360,000. State Street Corp increased its holdings in shares of KalVista Pharmaceuticals by 21.3% during the fourth quarter. State Street Corp now owns 1,911,691 shares of the specialty pharmaceutical company’s stock worth $30,874,000 after buying an additional 336,195 shares in the last quarter. Vestal Point Capital LP increased its holdings in shares of KalVista Pharmaceuticals by 152.0% during the fourth quarter. Vestal Point Capital LP now owns 1,890,000 shares of the specialty pharmaceutical company’s stock worth $30,524,000 after buying an additional 1,140,000 shares in the last quarter. Finally, Parkman Healthcare Partners LLC lifted its stake in shares of KalVista Pharmaceuticals by 155.5% in the 3rd quarter. Parkman Healthcare Partners LLC now owns 1,735,003 shares of the specialty pharmaceutical company’s stock valued at $21,132,000 after acquiring an additional 1,055,940 shares during the last quarter.

KalVista Pharmaceuticals News Summary

Here are the key news stories impacting KalVista Pharmaceuticals this week:

• Positive Sentiment: Unusual bullish options flow: traders bought 5,072 call options (≈569% above the average of 758), suggesting speculative or hedged bullish positioning that can amplify near-term upside interest in the shares.
• Positive Sentiment: Stifel Nicolaus raised its price target to $42 and reiterated a “buy” rating — a large upside vs. the current level that often attracts renewed investor attention and buying. Stifel price target raise
• Positive Sentiment: Needham & Company increased its target to $36 and kept a “buy” rating, reinforcing analyst conviction from multiple firms. Needham target raise
• Positive Sentiment: EKTERLY commercial launch showing strong initial revenue: KalVista reported $49.1M in EKTERLY revenue during an eight-month transition period — a material commercial proof point that supports revenue growth expectations. EKTERLY revenue report
• Positive Sentiment: Stock hit a new 52-week high after analyst upgrades and increased coverage, a technical signal that can attract momentum buyers. 52-week high / analyst upgrade
• Neutral Sentiment: Recent earnings materials (Q1 2025 call summary and transcript) have been published — useful for revisiting guidance and management commentary but the market reaction depends on details and forward guidance. Q1 2025 earnings call summary
• Negative Sentiment: Citizens Jmp trimmed its price target slightly from $29 to $28 (still a “market outperform”), a modest downtick in one analyst’s view that could temper upside expectations if other firms follow. Citizens Jmp target change

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.